Substituted quinazolinones as HCV inhibitors
View Patent ↗Inhibitors of HCV replication of formula (I) including stereochemically isomeric forms, salts, and solvates thereof, wherein R and R′ have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HCV inhibitors, in HCV therapy.
1. A compound of Formula (I)
or a stereoisomer thereof, wherein:
at least one of
independently is selected from a group consisting of
and the other
is independently selected from the group consisting of
R and R′ are independently selected from —CR 1 R 2 R 3 , aryl and —CR 1 R 2 R 3 substituted with 1 or 2 substituents selected from halo and methyl, or heterocycloalkyl, wherein
R 1 is selected from the group consisting of methyl; C 2-4 alkyl, optionally substituted with methoxy or hydroxy; and phenyl, optionally substituted with 1 or 2 substituents independently selected from halo and methyl;
R 2 is selected from the group consisting of hydroxy, amino, C 1-4 alkylamino, di-C 1-4 alkylamino, C 1-4 alkylcarbonylamino, and C 1-4 alkyloxycarbonylamino;
R 3 is hydrogen or C 1-4 alkyl;
or a pharmaceutically acceptable salt or solvate thereof.
2. The compound according to claim 1 , which is of Formula (Ia)
3. The compound of Formula (I) according to claim 1 , wherein at least one
independently is selected from the group consisting of
4. The compound of Formula (I) according to claim 1 , wherein at least one
independently is
5. The compound according to claim 1 , wherein R 1 is selected from the group consisting of C 2 alkyl substituted with methoxy; C 3 alkyl, optionally substituted with methoxy; branched C 4 alkyl; and phenyl, optionally substituted with 1 substituent selected from halo and methyl.
6. The compound according to claim 1 , wherein R 2 is C 1-4 alkylcarbonylamino or C 1-4 alkyloxycarbonylamino; and R 3 is hydrogen.
7. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.
8. A product containing (a) a compound according to claim 1 and (b) another hepatitis C virus inhibitor.
9. A method for treating a hepatitis C infection in a mammal, comprising administering to said mammal the compound according to claim 1 .